Evidence map›Paper›PMID 36298573›Full record

ArticleVaccines2022

Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity.

Alireza Abdollahi, Yeganeh Afsharyzad, Atefeh Vaezi, Alipasha Meysamie

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Alireza AbdollahiDepartment of Pathology, School of Medicine, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran 1416634793, Iran.
Yeganeh AfsharyzadDepartment of Microbiology, Faculty of Modern Sciences, The Islamic Azad University of Tehran Medical Sciences, Tehran 1416634793, Iran.
Atefeh VaeziCancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran.ORCID 0000-0002-1829-0494
Alipasha MeysamieDepartment of Community Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran 1416634793, Iran.ORCID 0000-0003-4223-4254
Iranian Institute for Health Sciences Research · IRIsfahan University of Medical Sciences · IRIslamic Azad University Medical Branch of Tehran · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is debate on the necessity of booster doses of COVID-19 vaccination, especially in countries with limited resources.

methodsThis cross-sectional study was conducted in a referral laboratory in Tehran, Iran. The level of COVID-19 antibodies was measured and compared between individuals regarding the number of COVID-19 vaccine shots.

resultsIn this study, 176 individuals with a mean age of 36.3 (±11.7) years participated. A total of 112 individuals received two doses of the COVID-19 vaccine, and 64 individuals received three doses. Level of all antibodies was higher in those who received three doses than in those who received two doses of the COVID-19 vaccine. Considering the SARS-CoV-2 Spike IgG, the difference was not statistically significant but for the SARS-CoV-2 RBD IgG and SARS-CoV-2 NAB the difference was statistically significant. Regarding to the background variables, receiving influenza vaccine in the past year, history of autoimmune diseases and past medical history of chicken pox showed a significant association with the number of vaccine doses received. Their effects on the outcome variables assessed with multivariate logistic regression analysis.

conclusionThe results of our study show that a booster dose of the COVID-19 vaccine enhances the antibody response.

Indexed as

booster doseneutralizing antibodyRBD antibodySARS-CoV-2spike antibodyvaccination

Identifiers

PMID36298573
PMCPMC9610198
OpenAlexW4306160124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.